Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 5, 1997, Pages 24-31

  Ninan, Philip T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; YOHIMBINE;

AGORAPHOBIA; BEHAVIOR THERAPY; COGNITIVE THERAPY; DRUG EFFICACY; DRUG RESPONSE; PANIC; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ALPRAZOLAM; BEHAVIOR THERAPY; CLINICAL TRIALS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FLUVOXAMINE; HUMANS; PANIC DISORDER; PLACEBOS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031006249     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Wilson GT. Behavior therapy. In: Karasu TB, chair. American Psychiatric Association Task Force on Treatment of Psychiatric Disorders, Washington, DC: American Psychiatric Press; 1989;3:2025-2036
2. Salzman C. Treatment with antianxiety agents. In: Karasu TB, chair. American Psychiatric Association Task Force on Treatment of Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1989;3:2036-2052
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
4. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacology (Berl) 1964;5:397-408
5. Hollister LE. Panic disorder: old wine in new bottles? Integrative Psychiatry 1992;8(2):75-90
6. Liebowitz MR, Fyer AJ, Gorman J, et al. Recent developments in the understanding and pharmacotherapy of panic attacks. Psychopharmacol Bull 1986;22:792-796
7. Barlow DH. Behavioral conception and treatment of panic. Psychopharmacol Bull 1986;22:802-806
8. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993;50:306-317
9. Shear MK, Maser JD. Standardized assessment for panic disorder research. Arch Gen Psychiatry 1994;51:346-354
10. Liebowitz MR. Functional classification of anxiety-panic. International Clinical Psychopharmacology 1993;8(suppl 1):47-52
11. Cassano GB, Perugi G, Musetti L. Comorbidity in panic disorder. Psychiatric Annals 1990;20:517-521
12. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991;48:851-855
13. de Beurs E, Dyck RV, van Balkom AJLM, et al. Assessing the clinical significance of outcome in agoraphobia research: a comparison of two approaches. Behavior Therapy 1994;25:147-158
14. Merz WA. Placebo response in panic disorder: a review. Eur Psychiatry 1994;9:123-127
15. Howard KI, Kopta SM, Krause MS, et al. The dose-effect relationship in psychotherapy. Am Psychol 1986:159-164
16. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway study of panic disorder, I: clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 1992;25:63-70
17. Ballenger JC, Burrows GD, Dupont R, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short term treatment. Arch Gen Psychiatry 1988;45:414-422
18. Leber P. Policy for the review of efficacy of NDAs by FDA. Division of neuropharmacological drug product. 1986;Doc33697p
19. Shear MK, Cooper AM, Klerman GL, et al. A psychodynamic model of panic disorder. Am J Psychiatry 1993;150:859-866
20. Barlow DH. Long-term outcome for patients with panic disorder treated with cognitive behavioral therapy. J Clin Psychiatry 1990;51(12, suppl A): 17-23
21. Beck AT, Sokol L, Clark DA, et al. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992;149:778-783
22. Shear MK, Pilkonis PA, Cloitre M, et al. Cognitive behavioral treatment compared with nonprescriptive treatment for panic disorder. Arch Gen Psychiatry 1994;51:395-401
23. Ballenger JC. Panic disorder: efficacy of current treatments. Psychopharmacol Bull 1993;29:477-486
24. Cross National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992;160:191-202
25. Oehrberg S, Christeansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomized double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
26. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121
27. den Boer JA, Westenberg HGM, Kamerbeek WDJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
28. den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74
29. Westenberg HGM, den Boer JA. Serotonin influencing drugs in the treatment of panic disorder. Psychopathology 1989;22(suppl 1):68-77
30. den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94
31. Westenberg HGM, den Boer JA. New findings in the treatment of panic disorder. Pharmacopsychiatry 1993;26(suppl):30-33
32. Hoehn-Saric R, McCleod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-326
33. Hoehn-Saric R, Fawcett J, Munjack DJ, et al. A multicenter, double-blind, placebo-controlled study of fluvoxamine in the treatment of panic disorder. Neuropsychopharmacology 1994;10(suppl 3):102S
34. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50
35. Woods S, Black D, Brown S, et al. Fluvoxamine in the treatment of panic disorder in outpatients: a double-blind, placebo-controlled study. Neuropsychopharmacology 1994;10(suppl 3):103S
36. de Beurs E, van Balkom JLM, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-691
37. Boyer W. Serotonin uptake inhibitors are superior to imipramine in alleviating panic attacks: a meta-analysis. In: Mendlewicz DG, Brunello RG, eds. Current Therapeutic Approaches to Panic and Other Anxiety Disorders. Basel, Switzerland: Karger, Int Acad Biomed Drug Res; 1994;8: 55-60
38. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-49
39. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-149